Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE-HNSCC: Volrustomig vs Observation in LA-HNSCC
NCT06129864Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Primary completion
- Apr 2030
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of volrustomig in head and neck squamous cell carcinoma (HNSCC), sponsored by AstraZeneca. Started Dec 2023; status: recruiting.
02
Drugs
volrustomig
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06129864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06129864.